Scientists have been able to engineer the T cells of HIV-infected patients to become resistant to the virus, and such cells were subsequently able to control HIV infection when patients were taken off of antiretroviral therapy (ART), including one patient whose blood levels of HIV became undetectable over the course of the phase I trial.